Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc./ US09061G1013 /
BM8
6/4/2024 7:57:14 AM
|
Chg.
+0.6600
|
Volume |
Bid6:40:17 PM |
Ask6:40:17 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
70.0400EUR
|
+0.95%
|
- Turnover: - |
71.6200Bid Size: 310 |
71.6400Ask Size: 310 |
13.45 bill.EUR |
- |
- |
Fundamentals
|
FY 2023 |
Growth (1Y) |
Per Share |
|
Earnings per Share: |
0.89 USD |
17.11% |
EPS Diluted: |
0.87 USD |
16.00% |
Revenues per Share: |
12.82 USD |
14.11% |
Book Value per Share: |
26.24 USD |
6.34% |
Cash Flow per Share: |
0.84 USD |
-10.49% |
Dividend per Share: |
- USD |
- |
Total |
in mill. |
|
Revenues: |
2,419.23 USD |
15.42% |
Net Income: |
167.65 USD |
18.43% |
Operating Cash Flow: |
159.26 USD |
- |
Cash and Cash Equivalents: |
755.13 USD |
- |
Valuation Ratios
|
Current |
Latest FY* |
P/E Ratio: |
86.75 |
108.34 |
P/S Ratio: |
6.02 |
7.52 |
P/BV ratio: |
2.94 |
3.67 |
P/CF Ratio: |
91.47 |
114.23 |
PEG: |
5.07 |
6.33 |
Earnings Yield: |
1.15% |
0.92% |
Dividend Yield: |
- |
- |
Market Capitalization |
|
Market Capitalization: |
13.45 bill. EUR |
16.48 bill. EUR |
Free Float Market Cap.: |
- EUR |
- EUR |
Market Cap. / Employee: |
- EUR |
- EUR |
Shares Outstanding: |
189.88 mill. |
|
Profitability
Gross Profit Margin: |
78.72% |
EBIT Margin: |
6.54% |
Net Profit Margin: |
6.93% |
Return on Equity: |
3.39% |
Return on Assets: |
2.45% |
Financial Strength
Liquidity I / Cash Ratio: |
64.16% |
Liquidity II / Quick Ratio: |
118.00% |
Liquidity III / Current Ratio: |
251.15% |
Debt / Equity Ratio: |
38.17% |
Dynam. Debt / Equity Ratio: |
1,186.78% |
Efficiency
Employees: |
- |
Personal Expenses / Employee: |
- USD |
Revenues / Employee: |
- USD |
Net Income / Employee: |
- USD |
Total Assets / Employee: |
- USD |
* Fiscal Year End: |
12/31/2023 |
Accounting Standard: |
US GAAP |